



TAR PUSTAKA

1. WHO Hepatitis C Fact sheet, updated July 2020. <http://www.who.int/mediacentre/factsheets/fs164/en/> (accessed 01 November 2020).
2. Rinanda T. Analisis molekuler genom virus hepatitis C serta peranannya dalam patogenesis infeksi. Jurnal Kedokteran Syiah Kuala. 2012;12(1):53-7.
3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of internal medicine. 2000 Feb 15;132(4):296-305.
4. Căruntu FA, Benea L. Acute hepatitis C virus infection: Diagnosis, pathogenesis, treatment. Journal of Gastrointestinal and Liver Diseases. 2006 Sep 1;15(3):249.
5. Westbrook RH, Dusheiko G. Natural history of hepatitis C. Journal of hepatology. 2014 Nov 1;61(1):S58-68.
6. Holzmann I, Tovo CV, Minmé R, Leal MP, Kliemann MP, Ubirajara C, Aquino AA, Araujo B, Almeida PR. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil. The Brazilian Journal of Infectious Diseases. 2018 Jul 1;22(4):317-22.
7. Bwa AH, Nangia G, Win ST, Maung ST, Han KA, Htar SS, Wine LY, Ko WW, Oo MP, Hlaing NK, Palecki J. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience. Journal of clinical and experimental hepatology. 2019 May 1;9(3):283-93.
8. Cory TJ, Mu Y, Gong Y, Kodidela S, Kumar S. Sofosbuvir+ velpatasvir+ voxilaprevir for the treatment of hepatitis C infection. Expert opinion on pharmacotherapy. 2018 May 3;19(7):749-57.
9. Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PloS one. 2019 Apr 4;14(4):e0214795.



1. Maynard M, Pradat P, Berthillon P, Picchio G, Voirin N, Martinot M, Marcellin P, Trepo C. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. *Journal of viral hepatitis.* 2003 Jul;10(4):318-23
11. Jackson WE, Everson GT. Sofosbuvir and velpatasvir for the treatment of hepatitis C. *Expert review of gastroenterology & hepatology.* 2017 Jun 3;11(6):501-5.
12. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. *New England Journal of Medicine.* 2015 Dec 31;373(27):2608-17.
13. Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, Yatsuhashi H, Takikawa Y, Kanda T, Sakamoto M, Tamori A. Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. *Journal of gastroenterology.* 2019 Jan 25;54(1):87-95.
14. Gayam V, Mandal AK, Khalid M, Mukhtar O, Gill A, Garlapati P, Khalid M, Mansour M. Sofosbuvir based regimens in the treatment of chronic hepatitis C with compensated liver cirrhosis in community care setting. *International journal of hepatology.* 2018 Aug 1;2018.
15. Butt N, Muhammad I, Abou Bakr A, Akhtar Z, Ali M, Muhammad SS, Maheshwary N. Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial. *Cureus.* 2020 Jan;12(1).
16. Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, Foxton M, Rodriguez CF, Esteban R. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. *Journal of hepatology.* 2019 Oct 1;71(4):660-5.



1. Ahmed H, Abushouk AI, Attia A, Gadelkarim M, Gabr M, Negida A, Abdel-Daim MM. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis. *Journal of infection and public health*. 2018 Mar 1;11(2):156-64.
18. Gaur N, Malhotra V, Agrawal D, Singh SK, Beniwal P, Sharma S, Jhorawat R, Rathore V, Joshi H. Sofosbuvir–velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. *Journal of clinical and experimental hepatology*. 2020 May 1;10(3):189-93.
19. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and -3 clinical trials. *Clinical Infectious Diseases*. 2016 Oct 15;63(8):1042-8.
20. Younossi ZM, Stepanova M, Charlton M, Curry MP, O'Leary JG, Brown RS, Hunt S. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. *The Lancet Gastroenterology & Hepatology*. 2016 Oct 1;1(2):122-32.
21. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. *New England Journal of Medicine*. 2015 Dec 31;373(27):2618-28.



Lampiran 1. Biodata Penulis

CURRICULUM VITAE



Nama Lengkap : Jelvelerie Jaumi
Nama Panggilan : Jelve
NIM : C011171829
Tempat, Tanggal Lahir : Malaysia, 01 Januari 1998
Jenis Kelamin : Perempuan
Agama : Katolik
Golongan Darah : O
Email : jelveleriejaumi@gmail.com
No. HP : 087819466118

Riwayat Pendidikan

No.	Jenjang Pendidikan	Nama Sekolah	Tempat	Tahun
1	TK	Tabika Kemas	Sabah	2003-2004
2	SD	SK Kapayan Baru	Sabah	2005-2010
3	SMP	SM Sains Sabah	Sabah	2011-2013
4	SMA	SM Sains Sabah	Sabah	2014-2015
5	Foundation	ASASI Dengkil	Selangor	2016-2017